Shared on21 Aug 25Fair value Increased 9.61%
The increase in WuXi Biologics (Cayman)’s consensus price target reflects improved market sentiment driven by a higher future P/E and a slight uptick in net profit margin, raising the fair value estimate from HK$33.29 to HK$34.82. What's in the News Dundalk, Ireland facility approved by EMA as a commercial manufacturing site, marking first commercial biologic launch from WuXi Biologics' Ireland site and reinforcing its global regulatory compliance with a 100% inspection success rate.
Shared on23 Apr 25Fair value Decreased 0.035%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 3.31%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 5.20%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 18%
AnalystConsensusTarget has increased revenue growth from 13.5% to 15.0% and increased future PE multiple from 19.4x to 22.4x.
Shared on26 Mar 25Fair value Decreased 8.59%
AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.
Shared on12 Mar 25Fair value Decreased 14%
AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.